We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+13.5%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$219M
AUM Growth
+$3.33M
Cap. Flow
-$9.09M
Cap. Flow %
-4.16%
Top 10 Hldgs %
53.49%
Holding
80
New
23
Increased
12
Reduced
26
Closed
8

Top Buys

Rank Stock Value
1
RDUS
Radius Health, Inc.
RDUS
+$4.26M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$3.77M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$3.35M
4
SAGE
Sage Therapeutics
SAGE
+$3.05M
5
SNY icon
Sanofi
SNY
+$2.95M

Top Sells

Rank Stock Value
1
ABLX
Ablynx NV
ABLX
+$9.92M
2
AVXS
AveXis, Inc. Common Stock
AVXS
+$9.66M
3
ENSG icon
The Ensign Group
ENSG
+$5.27M
4
ARRY
Array Biopharma Inc
ARRY
+$4.92M
5
ARNA
Arena Pharmaceuticals Inc
ARNA
+$3.72M

Sector Composition

Rank Sector Weight
1 Healthcare 72.69%
2 Real Estate 11.35%
3 Industrials 8.34%
4 Miscellaneous 6.63%
5 Financials 0.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARGX icon
26
argenx
ARGX
$64B
$2.02M 0.92%
24,384
-11,400
-32% -$1.02M
ASND icon
27
Ascendis Pharma A/S
ASND
$16.3B
$2M 0.91%
30,054
+6,000
+25% +$395K
IVC
28
DELISTED
Invacare Corporation
IVC
$1.86M 0.85%
99,902
– –
CTRE icon
29
CareTrust REIT
CTRE
$9.22B
$1.71M 0.78%
101,264
-7,000
-6% -$105K
MDCO
30
DELISTED
Medicines Co
MDCO
$1.44M 0.66%
39,317
– –
CBAY
31
DELISTED
Cymabay Therapeutics
CBAY
$1.44M 0.66%
+107,096
New +$1.34M
AMRN
32
Amarin Corp
AMRN
$295M
$1.42M 0.65%
23,000
+10,500
+84% +$650K
PBYI icon
33
Puma Biotechnology
PBYI
$468M
$1.42M 0.65%
23,924
+1,000
+4% +$58K
TNDM icon
34
Tandem Diabetes Care
TNDM
$1.49B
$1.35M 0.62%
+61,300
New +$754K
HAE icon
35
Haemonetics
HAE
$4.73B
$1.31M 0.6%
14,646
– –
IMMU
36
DELISTED
Immunomedics Inc
IMMU
$1.3M 0.6%
+55,000
New +$1.11M
MYOK
37
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$1.29M 0.59%
25,950
-16,050
-38% -$777K
MDGL icon
38
Madrigal Pharmaceuticals
MDGL
$12.3B
$1.26M 0.58%
+4,500
New +$790K
EHTH icon
39
eHealth
EHTH
$38.4M
$1.25M 0.57%
56,546
-18,000
-24% -$347K
ELV icon
40
Elevance Health
ELV
$85.5B
$1.19M 0.54%
5,000
-1,000
-17% -$232K
AKRX
41
DELISTED
Akorn Inc
AKRX
$1.16M 0.53%
+70,000
New +$1.07M
TGTX icon
42
TG Therapeutics
TGTX
$8.26B
$1.05M 0.48%
80,000
-70,000
-47% -$963K
DRNA
43
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$1.04M 0.48%
+85,000
New +$1.07M
CNC icon
44
Centene
CNC
$32B
$986K 0.45%
16,000
-4,000
-20% -$231K
BCRX icon
45
BioCryst Pharmaceuticals
BCRX
$2.51B
$854K 0.39%
148,959
– –
CLLS
46
Cellectis
CLLS
$342M
$849K 0.39%
+30,000
New +$893K
ARRY
47
DELISTED
Array Biopharma Inc
ARRY
$812K 0.37%
48,412
-309,315
-86% -$4.92M
VCEL icon
48
Vericel Corp
VCEL
$2.1B
$726K 0.33%
+74,837
New +$932K
ABUS icon
49
Arbutus Biopharma
ABUS
$1B
$712K 0.33%
97,495
-20,000
-17% -$119K
IOVA icon
50
Iovance Biotherapeutics
IOVA
$3.63B
$704K 0.32%
55,000
-10,000
-15% -$146K
1
2
3 4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q2 2018 Portfolio in Review

As of Q2 2018, Eversept Partners held 80 positions worth $219M, up 1.5% from $215M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Eversept Partners withdrew a net $9.09M in Q2 2018, closing 8 positions and reducing 26 holdings. Its most notable exit was Ablynx NV, an estimated $9.92M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 75% a quarter earlier, followed by Real Estate and Industrials.

Against the trend, Eversept Partners opened a new position in Sarepta Therapeutics worth $5.29M.

  • Eversept Partners's largest Q2 2018 buy was Sarepta Therapeutics: 40,000 shares worth $5.29M.
  • Eversept Partners added most to Radius Health, Inc. in Q2 2018, an estimated $4.26M increase.
  • Eversept Partners's biggest Q2 2018 reduction was The Ensign Group, cutting an estimated $5.27M.
  • Eversept Partners fully exited Ablynx NV in Q2 2018, selling an estimated $9.92M.
  • Eversept Partners's ten largest holdings make up 53% of its $219M portfolio in Q2 2018.
  • Eversept Partners opened 23 new positions and closed 8 in Q2 2018.
  • Eversept Partners's portfolio value rose 1.5% quarter-over-quarter to $219M.

Based on Eversept Partners's 13F filing for Q2 2018, filed 14 Aug 2018.